7-(1,1-Dimethylethyl)-3,4-dihydro-6-(methoxymethoxy)-2-methyl-2H-1-benzopyran-2-methanol | 199339-73-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 7-(1,1-Dimethylethyl)-3,4-dihydro-6-(methoxymethoxy)-2-methyl-2H-1-benzopyran-2-methanol
• 英文别名: [7-tert-butyl-6-(methoxymethoxy)-2-methyl-3,4-dihydrochromen-2-yl]methanol
• CAS: 199339-73-6
• 化学式: C₁₇H₂₆O₄
• 分子量: 294.391
• InChiKey: BDQBVQGZWMGXBQ-UHFFFAOYSA-N

物化性质

• 沸点：
  414.2±45.0 °C(Predicted)
• 密度：
  1.059±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  47.9
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  7-(1,1-Dimethylethyl)-3,4-dihydro-6-(methoxymethoxy)-2-methyl-2H-1-benzopyran-2-methanol 在 吡啶 、 硫酸 、 sodium hydride 、 溶剂黄146 作用下， 生成
  参考文献：
  名称：

  Studies on hindered phenols and analogs. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation

  摘要：

  A series of hindered phenols were investigated as hypolipidemic and/or hypoglycemic agents with ability to inhibit lipid peroxidation. 1,3-Benzoxathioles (9 and 22), phenoxypentanoic acid (34), phenoxypentanol (35a), phenoxynonanol (35b), phenylchloropropionic acid having a chromanyl group (25), and a thiazolidine compound (27) derived from 25, all having a hindered phenol group, were prepared and examined. Compound 27 showed the expected biological properties in vivo and in vitro without any liver weight increase. Biological activities of the analogous thiazolidine compounds, 43-58, were compared. Thus, (+/-)-5-[4-[(6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)methoxy]- benzyl]-2,4-thiazolidinedione (27) (CS-045) was found to have all of our expected properties and was selected as a candidate for further development as a hypoglycemic and hypolipidemic agent.

  DOI：

  10.1021/jm00122a022
• 作为产物：
  描述：

  氯甲基甲基醚 、 在 sodium hydride 作用下， 生成 7-(1,1-Dimethylethyl)-3,4-dihydro-6-(methoxymethoxy)-2-methyl-2H-1-benzopyran-2-methanol
  参考文献：
  名称：

  Studies on hindered phenols and analogs. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation

  摘要：

  A series of hindered phenols were investigated as hypolipidemic and/or hypoglycemic agents with ability to inhibit lipid peroxidation. 1,3-Benzoxathioles (9 and 22), phenoxypentanoic acid (34), phenoxypentanol (35a), phenoxynonanol (35b), phenylchloropropionic acid having a chromanyl group (25), and a thiazolidine compound (27) derived from 25, all having a hindered phenol group, were prepared and examined. Compound 27 showed the expected biological properties in vivo and in vitro without any liver weight increase. Biological activities of the analogous thiazolidine compounds, 43-58, were compared. Thus, (+/-)-5-[4-[(6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)methoxy]- benzyl]-2,4-thiazolidinedione (27) (CS-045) was found to have all of our expected properties and was selected as a candidate for further development as a hypoglycemic and hypolipidemic agent.

  DOI：

  10.1021/jm00122a022

文献信息

• [DE] NEUE THIAZOLIDINDIONE, VERFAHREN ZU IHRER HERSTELLUNG UND DIESE ENTHALTENDE ARZNEIMITTEL<br/>[EN] NEW THIAZOLIDINEDIONES, PROCESS FOR PREPARING THE SAME AND MEDICAMENTS CONTAINING THE SAME<br/>[FR] NOUVELLES THIAZOLIDINEDIONES, LEUR PROCEDE DE PREPARATION ET MEDICAMENTS LES CONTENANT
  申请人：BOEHRINGER MANNHEIM GMBH

  公开号：WO1997043284A1

  公开（公告）日：1997-11-20

  (DE) Verbindungen der Formel (I), in welcher A ein Schwefelatom oder die Gruppe -CH=CH-, R Wasserstoff oder eine -CH2-OR5-Gruppe darstellt, in der R5 Wasserstoff oder Acyl bedeutet, R1 und R3 Wasserstoff oder Methyl und R2 Methyl oder t-Butyl bedeutet, deren Tautomere, Enantiomere, Diastereomere und physiologisch verträglichen Salze, Verfahren zu deren Herstellung sowie Arzneimittel mit antidiabetischer Wirkung, die diese Substanzen enthalten.(EN) Compounds of formula (I) are disclosed, as well as their tautomers, enantiomers, diastereomers and physiologically tolerable salts, a process for preparing the same and medicaments with an antidiabetic effect which contain these substances. In the formula, A is a sulphur atom or the group -CH=CH-; R is hydrogen or a -CH2-OR5 group in which R5 stands for hydrogen or acyl; R1 and R3 are hydrogen or methyl; and R2 is methyl or t-butyl.(FR) L'invention concerne des composés de formule (I), ainsi que leurs tautomères, énantiomères, diastéréomères et sels physiologiquement tolérables, leur procédé de préparation et des médicaments à effet antidiabétique les contenant. Dans cette formule, A est un atome de soufre ou bien le groupe CH=CH-; R est hydrogène ou un groupe -CH2-OR5 dans lequel R5 représente hydrogène ou acyle, R1 et R3 sont hydrogène ou méthyle, et R2 est méthyle ou t-butyle.

  该发明涉及化合物及其同分异构体、异构体、多构体以及生理相容性盐化合物，还包括制备上述化合物的方法和含有此类化合物的药品。在该结构式中，A代表硫原子或-CH=CH-基团；R代表H或-CH2-OR5基团，其中R5代表H或酰基；R1和R3代表H或甲基；R2代表甲基或t-Butyl。